Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature

International Journal of Cancer

Volumn 125, Issue 6, 2009, Pages 1446-1453

  Uneda, Shima ^a   Toi, Hirofumi ^a   Tsujie, Tomoko ^a   Tsujie, Masanori ^a   Harada, Naoko ^a   Tsai, Hilda ^a   Seon, Ben K ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Antiangiogenesis; Endoglin; Metastasis; Monoclonal antibodies; Vascular targeting

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY SN6A; MONOCLONAL ANTIBODY SN6J; MONOCLONAL ANTIBODY SN6K; RICIN A; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; MOUSE; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; SKIN TUMOR; TREATMENT RESPONSE; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; COLLAGEN; DRUG COMBINATIONS; FEMALE; HUMANS; LAMININ; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PROTEOGLYCANS; RECEPTORS, CELL SURFACE; TUMOR CELLS, CULTURED;

EID: 68249147445     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24482     Document Type: Article

References (50)

1. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448-56.
2. Christofori G. New signals from the invasive front. Nature 2006; 441:444-50.
3. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006;12:895-904.
4. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-95.
5. Haruta Y, Seon BK. Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6. Proc Natl Acad Sci USA 1986;83:7898-902.
6. Gougos A, Letarte M. Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 1988;141:1925-33.
7. Seon BK. Expression of endoglin (CD105) in tumor blood vessels. Int J Cancer 2002;99:310-11.
8. Bellon T, Corbi A, Lastres P, Cales C, Cebrian M, Vera S, Cheifetz S, Massague J, Letarte M, Bernabeu C. Identification and expression of two forms of the human transforming growth factor-β-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 1993; 23:2340-5.
9. Westphal JR, Willems HW, Schalkwijk CJ, Ruiter DJ, de Waal RM. A new 180-kDa dermal endothelial cell activation antigen: in vitro and in situ characteristics. J Invest Dermatol 1993;100:27-34.
10. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW, Letarte M, Vitetta ES, Thorpe PE. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995;1:1623-34.
11. Seon BK, Matsuno F, Haruta Y, Kondo M, Barcos M. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin. Clin Cancer Res 1997;3:1031-44.
12. Miller DW, Graulich W, Karges B, Stahl S, Ernst M, Ramaswamy A, Sedlacek HH, Muller R, Adamkiewicz J. Elevated expression of endoglin, a component of the TGF-β-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 1999;81: 568-72.
13. Wang JM, Kumar S, Pye D, van Agthoven AJ, Krupinski J, Hunter RD. A monoclonal antibody detects heterogeneity in vascular endothelium of tumours and normal tissues. Int J Cancer 1993;54: 363-70.
14. Li DY, Sorensen LK, Brooke BS, Urness LD, Davis EC, Taylor DG, Boak BB, Wendel DP. Defective angiogenesis in mice lacking endoglin. Science 1999;284:1534-7.
15. Arthur HM, Ure J, Smith AJ, Renforth G, Wilson DI, Torsney E, Charlton R, Parums DV, Jowett T, Marchuk DA, Burn J, Diamond AG. Endoglin, an ancillary TGFβ receptor, is required for extraembryonic angiogenesis and plays a key role in heart development. Dev Biol 2000;217:42-53.
16. Cheifetz S, Bellon T, Cales C, Vera S, Bernabeu C, Massague J, Letarte M. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 1992; 267:19027-30.
17. Yamashita H, Ichijo H, Grimsby S, Moren A, ten Dijke P, Miyazono K. Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-β. J Biol Chem 1994;269: 1995-2001.
18. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A, Bernabeu C. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-β receptors I and II. J Biol Chem 2002; 277:29197-209.
19. Velasco S, Alvarez-Munoz P, Pericacho M, Dijke PT, Bernabeu C, Lopez-Novoa JM, Rodriguez-Barbero A. L- and S-endoglin differentially modulate TGFβ1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts. J Cell Sci 2008;121:913-19.
20. Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM, Bundred N. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 1999;59:856-61.
21. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, Yamada T, Hanaoka N, Inui K, Wada H. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001;7:3410-15.
22. Li C, Gardy R, Seon BK, Duff SE, Abdalla S, Renehan A, O'Dwyer ST, Haboubi N, Kumar S. Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer 2003;88:1424-31.
23. Charpin C, Dales JP, Garcia S, Carpentier S, Djemli A, Andrac L, Lavaut MN, Allasia C, Bonnier P. Tumor neoangiogenesis by CD31 and CD105 expression evaluation in breast carcinoma tissue microarrays. Clin Cancer Res 2004;10:5815-19.
24. Matsuno F, Haruta Y, Kondo M, Tsai H, Barcos M, Seon BK. Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies. Clin Cancer Res 1999;5:371-82.
25. 125I-labeled anti-endoglin monoclonal antibodies. Int J Cancer 1999;82:737-42.
26. Takahashi N, Haba A, Matsuno F, Seon BK. Antiangiogenic therapy of established tumors in human skin/severe combined immunodefi-ciency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 2001;61:7846-54.
27. Tsujie M, Uneda S, Tsai H, Seon BK. Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites. Int J Oncol 2006; 29:1087-94.
28. Tsujie M, Tsujie T, Toi H, Uneda S, Shiozaki K, Tsai H, Seon BK. Anti-tumor activity of an anti-endoglin monoclonal antibody is enhanced in immunocompetent mice. Int J Cancer 2008;122:2266-73.
29. Shiozaki K, Harada N, Greco WR, Haba A, Uneda S, Tsai H, Seon BK. Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin. Cancer Immunol Immunother 2006;55:140-50. 30. Takahashi N, Kawanishi-Tabata R, Haba A, Tabata M, Haruta Y, Tsai H, Seon BK. Association of serum endoglin with metastasis in patients with colorectal, breast, and other solid tumors, and suppressive effect of chemotherapy on the serum endoglin. Clin Cancer Res 2001;7:524-32.
30. She X, Matsuno F, Harada N, Tsai H, Seon BK. Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-b in suppression of growth of human endothelial cells. Int J Cancer 2004;108: 251-7.
31. Corbett TH, Griswold DP, Jr, Roberts BJ, Peckham JC, Schabel FM, Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 1975;35:2434-9.
32. Ohnishi Y, Sakamoto T, Fujii H, Kimura F, Murata J, Tazawa K, Fujimaki M, Sato Y, Kondo M, Une Y, Uchino J, Saiki I. Characterization of a liver metastatic variant of murine colon 26 carcinoma cells. Tumour Biol 1997;18:113-22.
33. Wong CW, Song C, Grimes MM, Fu W, Dewhirst MW, Muschel RJ, Al-Mehdi AB. Intravascular location of breast cancer cells after spontaneous metastasis to the lung. Am J Pathol 2002;161:749-53.
34. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
35. Dvorak HF, Nagy JA, Dvorak AM. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 1991;3:77-85.
36. Jain RK. Barriers to drug delivery in solid tumors. Sci Am 1994; 271:58-65.
37. Kerbel R, Ellis L. Angiogenesis. In: DeVita V, Lawrence T, Rosenberg S, eds. Cancer: principles and practice of oncology, 8th ed.,Vol.1. Philadelphia: Lippincott Williams & Wilkins, 2008.103-16.
38. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 1982;45:136-9.
39. Bicknell R, Harris AL. Anticancer strategies involving the vasculature: vascular targeting and the inhibition of angiogenesis. Semin Cancer Biol 1992;3:399-407.
40. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27.
41. Horsman MR, Siemann DW. Pathophysiologic effects of vasculartargeting agents and the implications for combination with conventional therapies. Cancer Res 2006;66:11520-39.
42. Seon BK, Kumar S. CD105 antibody for targeting of tumor vascular endothelial cells. In: Fan T-PD, Kohn EC, eds. New angiotherapy. Totowa, NJ: Humana Press, 2002. 499-515.
43. Folkman J. Antiangiogenesis agents. In: DeVita V, Hellman S, Rosenberg S, eds. Cancer: principles and practice of oncology, 6th edn. Philadelphia: Lippincott Williams & Wilkins, 2001. 509-19.
44. Seon BK, Negoro S, Barcos MP. Monoclonal antibody that defines a unique human T-cell leukemia antigen. Proc Natl Acad Sci USA 1983;80:845-9.
45. Okazaki M, Luo Y, Han T, Yoshida M, Seon BK. Three new monoclonal antibodies that define a unique antigen associated with prolymphocytic leukemia/non-Hodgkin's lymphoma and are effectively internalized after binding to the cell surface antigen. Blood 1993;81: 84-94.
46. Munoz R, Arias Y, Ferreras JM, Rojo MA, Gayoso MJ, Nocito M, Benitez J, Jimenez P, Bernabeu C, Girbes T. Targeting a marker of the tumour neovasculature using a novel anti-human CD105-immunotoxin containing the non-toxic type 2 ribosome-inactivating protein nigrin b. Cancer Lett 2007;256:73-80.
47. Volkel T, Holig P, Merdan T, Muller R, Kontermann RE. Targeting of immunoliposomes to endothelial cells using a single-chain Fv fragment directed against human endoglin (CD105). Biochim Biophys Acta 2004;1663:158-66.
48. Fonsatti E, Jekunen AP, Kairemo KJ, Coral S, Snellman M, Nicotra MR, Natali PG, Altomonte M, Maio M. Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res 2000;6:2037-43.
49. Bredow S, Lewin M, Hofmann B, Marecos E, Weissleder R. Imaging of tumour neovasculature by targeting the TGF-β binding receptor endoglin. Eur J Cancer 2000;36:675-81.
50. m-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target. Int J Cancer 2004; 109:436-41.